NCT07710105
Ocrevus Zunovo for MS: Mixed Methods
Recruiting
Not specifiedAges 18+ObservationalNorthwestern UniversityInvestigator-initiated
~150 participants
Updated 2026-07-20 on ClinicalTrials.gov
What's tested:Clinical QuestionnairesSemi-Structured InterviewsOcrevus Zunovo
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Patient Satisfaction and Treatment Persistence
Measured over From enrollment to 12-month follow-up visit
Conditions
Where it's being run
1 sites across 1 statesIllinois1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age of 18 years or older
Resident of the USA
Seen at Northwestern Medicine
Meets diagnostic criteria (2024) for MS, either RMS or PPMS
Diagnosis of MS (G35) on file by a neurologist
Wants to start or restart a DMT for MS
Willing to be in a 12-month follow up study
Exclusion
Unclear diagnosis of MS
Incarcerated
Unable to provide informed consent
Current participant in an MS or any experimental therapy clinical trial
Moribund
Unable to speak a language for which consent processes are available at Northwestern Hospitals
Currently taking a DMT that has not been washed out (e.g. recent treatment with Cladribine, Natalizumab, sphingosine 1-phosphate inhibitor, implying the last DMT is still actively immunosuppressing the patient)
Current chemotherapy
History of stem cell transplant, CAR-T or other chemo-ablative procedures
Unwilling to complete surveys over the course of the following 12 months
No access to computer or telephone
Prior allergic reaction or intolerance to Ocrelizumab IV or SubQ or any monoclonal antibody therapy
Hypogammaglobulinemia IgG level \<500
Leukopenia \<2.0
Active hepatitis or latent hepatitis B
Elevated liver enzymes 3 times the upper limit of normal
Tuberculosis
Current serious infection, e.g. COVID-19, shingles, active pneumonia, progressive multifocal leukoencephalopathy, etc.
Currently pregnant, breastfeeding, or a person of childbearing capacity who is sexually active without a documented plan of current contraceptive methods.
Any other diagnosis or reason deemed to make the participant unfit for participation by the study PI
What this trial measures
- Patient Satisfaction and Treatment PersistenceFrom enrollment to 12-month follow-up visit
For MS patients treated with OZ, to measure MS patient satisfaction and treatment persistence on Ocrevus at 6 and 12 months.